New Study Finds Weight Loss Drugs Could Increase Risk of Stomach Paralysis and Gastrointestinal Issues
A recent study published in JAMA has raised concerns about the potential adverse effects of popular weight loss drugs, including Wegovy and Ozempic. The study, conducted by The University of British Columbia (UBC), is the first large-scale epidemiological study to examine these drugs’ effects on non-diabetic patients using them specifically for weight loss.
The study found that the risk of stomach paralysis, also known as gastroparesis, was linked to a class of medications known as GLP-1 receptor agonists, which includes Ozempic, Wegovy, Rybelsus, and Saxenda. These drugs are commonly prescribed for diabetes management and weight loss. Furthermore, the drugs were also associated with a higher risk of pancreatitis and bowel obstruction.
To conduct the study, UBC researchers analyzed health insurance claim records for approximately 16 million patients in the United States who were prescribed these medications between 2006 and 2020. The researchers compared the risks of taking GLP-1 agonists to those of another weight loss drug called bupropion-naltrexone and found that those who took GLP-1 agonists had a higher risk of stomach paralysis, pancreatitis, and bowel obstruction.
It is important to note that the study did not assess whether stomach paralysis caused by these drugs was temporary or permanent. However, the researchers recommend that regulatory agencies and drugmakers update the warning labels for GLP-1 medications to include the risk of gastroparesis. They emphasize that the decision to take these drugs should be individually assessed, taking into consideration the potential benefits and risks for each patient.
The study does have some limitations. Although the researchers analyzed a large dataset, there may be confounding factors that could affect the results. Additionally, the data analyzed spanned from 2006 to 2020, before Wegovy was on the market.
In response to the study’s findings, Novo Nordisk, the manufacturer of Ozempic and Wegovy, stated that gastrointestinal events are a known side effect of GLP-1 drugs and are typically mild to moderate in severity and of short duration. They assert that the safety and efficacy of their GLP-1 drugs are supported by product labeling and approved indications.
As more research is conducted on the risks and benefits of weight loss drugs, it is crucial for healthcare professionals and patients to stay informed and carefully weigh the potential risks and benefits before initiating treatment. The findings of this study highlight the importance of considering individual factors and consulting with healthcare providers when making decisions about weight loss medications.
Analyst. Amateur problem solver. Wannabe internet expert. Coffee geek. Tv guru. Award-winning communicator. Food nerd.